Palmar plantar erythrodysesthesia natural history, complications, and prognosis
Palmar plantar erythrodysesthesia Microchapters |
Differentiating Palmar plantar erythrodysesthesia from other Diseases |
---|
Diagnosis |
Treatment |
Palmar plantar erythrodysesthesia natural history, complications, and prognosis On the Web |
American Roentgen Ray Society Images of Palmar plantar erythrodysesthesia natural history, complications, and prognosis |
FDA on Palmar plantar erythrodysesthesia natural history, complications, and prognosis |
CDC on Palmar plantar erythrodysesthesia natural history, complications, and prognosis |
Palmar plantar erythrodysesthesia natural history, complications, and prognosis in the news |
Blogs on Palmar plantar erythrodysesthesia natural history, complications, and prognosis |
Directions to Hospitals Treating Palmar plantar erythrodysesthesia |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
OR
Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
OR
Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [#]%.
Natural History, Complications, and Prognosis
Natural History
- The symptoms of PPE usually develop 1–21 days after higher-dose pulse therapies and up to 2-10 months after continuous low-dose therapies.
- PPE usually occurs
- PPE appears to be dose-dependent.
- Both peak drug concentration and total cumulative dose determine its occurrence since both bolus infusions and continuous low-dose administration can cause a dose-dependent drug reaction [1] [2][3] [4]
- In addition, combined administration of two chemotherapy drug which both can cause PPE usually results in an increase in the frequency and severity of PPE.
Complications
- Common complications of [disease name] include:
- [Complication 1]
- [Complication 2]
- [Complication 3]
Prognosis
- Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [--]%.
- Depending on the extent of the [tumor/disease progression] at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as poor/good/excellent.
- The presence of [characteristic of disease] is associated with a particularly [good/poor] prognosis among patients with [disease/malignancy].
- [Subtype of disease/malignancy] is associated with the most favorable prognosis.
- The prognosis varies with the [characteristic] of tumor; [subtype of disease/malignancy] have the most favorable prognosis.
References
- ↑ Baer MR, King LE, Wolff SN (1985). "Palmar-plantar erythrodysesthesia and cytarabine". Ann Intern Med. 102 (4): 556. doi:10.7326/0003-4819-102-4-556_1. PMID 3977204.
- ↑ Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG (1989). "A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study". J Clin Oncol. 7 (4): 425–32. doi:10.1200/JCO.1989.7.4.425. PMID 2926468.
- ↑ Herzig RH, Wolff SN, Lazarus HM, Phillips GL, Karanes C, Herzig GP (1983). "High-dose cytosine arabinoside therapy for refractory leukemia". Blood. 62 (2): 361–9. PMID 6223674.
- ↑ Kroll SS, Koller CA, Kaled S, Dreizen S (1989). "Chemotherapy-induced acral erythema: desquamating lesions involving the hands and feet". Ann Plast Surg. 23 (3): 263–5. PMID 2528937.